GSK plc (LON: GSK)

London flag London · Delayed Price · Currency is GBP · Price in GBX
1,312.05
+12.05 (0.93%)
Nov 21, 2024, 12:44 PM BST
-6.99%
Market Cap 53.05B
Revenue (ttm) 31.31B
Net Income (ttm) 2.51B
Shares Out 4.08B
EPS (ttm) 0.61
PE Ratio 21.39
Forward PE 7.90
Dividend 0.58 (4.46%)
Ex-Dividend Date Nov 14, 2024
Volume 1,228,891
Open 1,300.00
Previous Close 1,300.00
Day's Range 1,300.00 - 1,320.07
52-Week Range 1,282.50 - 1,823.50
Beta 0.31
Analysts n/a
Price Target n/a
Earnings Date Oct 30, 2024

About GSK plc

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled... [Read more]

Sector Healthcare
Founded 1715
Employees 70,212
Stock Exchange London Stock Exchange
Ticker Symbol GSK
Full Company Profile

Financial Performance

In 2023, GSK plc's revenue was 30.33 billion, an increase of 3.42% compared to the previous year's 29.32 billion. Earnings were 4.93 billion, a decrease of -67.05%.

Financial Statements

News

GSK share price is imploding: is it safe to buy the dip?

The GSK share price has been in a strong freefall after peaking at 1,785p in September. Most recently, the GSK stock retreated for five consecutive weeks and reached its lowest level since October las...

2 days ago - Invezz

GSK drug meets main goal in late-stage study to treat relentless itch

British drugmaker GSK said on Tuesday its experimental therapy, linerixibat, met its main goal in a late-stage trial to treat patients with a so-called relentless itch associated with a rare autoimmun...

2 days ago - Reuters

As Drug Maker Stocks Fall, Pressure Builds On PhRMA To Derail RFK, Jr.

Stocks of major drug makers and biotech companies tumbled in trading late this week after President-elect Donald Trump announced that he wants vaccine skeptic Robert F. Kennedy Jr. to lead the U.S. De...

5 days ago - Forbes

Vaccine stocks hit by Robert Kennedy Jr nomination

GSK, Sanofi and Moderna shares all sink after Donald Trump chooses vaccine sceptic as top US health official

5 days ago - Financial Times

GSK plc (GSK) Guggenheim's Inaugural Healthcare Innovation Conference (Transcript)

GSK plc (NYSE:GSK) Guggenheim's Inaugural Healthcare Innovation Conference November 12, 2024 2:00 PM ETCompany ParticipantsEmma Walmsley - Chief Executive...

5 days ago - Seeking Alpha

European And US Vaccine Stocks Are Under Pressure - Here's WHy

Some large European and U.S. vaccine maker stocks have fallen in reaction to Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services.

5 days ago - Benzinga

Pharma shares hit as Trump picks RFK Jr to lead health department

Appointment of vaccine critic knocks some of world’s biggest drugmakers including Moderna, AstraZeneca and GSK Who is RFK Jr and what are his likely top priorities? Business live – latest updates Inve...

6 days ago - The Guardian

Vaccine maker stocks fall on reports Trump plans to tap RFK Jr. to lead HHS

Shares of Moderna, Novavax, Pfizer, BioNTech and GSK closed lower on Thursday.

6 days ago - CNBC

GSK Raises Prospects For Withdrawn Blood Cancer Drug Blenrep To Return To US Market - Here's Why

On Thursday, GSK plc (NYSE: GSK) released headline results from a planned interim analysis of the DREAMM-7 head-to-head phase 3 trial of Blenrep (belantamab mafodotin) in combination with bortezomib ...

6 days ago - Benzinga

GSK hails progress for withdrawn blood cancer drug

UK pharma group posts ‘statistically significant’ trial results for Blenrep when combined with another treatment

7 days ago - Financial Times

GSK's Blenrep Shows Promise in Combination Therapy for Blood Cancer

GSK's Blenrep Shows Promise in Combination Therapy for Blood Cancer

7 days ago - GuruFocus

GSK’s Withdrawn Blood Cancer Drug Paves Path Back to Market

GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, further boosting the prospects of bringing the previously withdrawn medicine bac...

7 days ago - BNN Bloomberg

RFK Jr.'s Impact on Healthcare Policy: Investors Weigh Risks and Opportunities

Emily Field from Barclays and Lance Wilks share insights on how RFK Jr.'s influence could affect stocks in the pharmaceutical and healthcare sectors, including companies like GSK, Sanofi, and Novo Nor...

8 days ago - CNBC

Ojjaara (momelotinib) approved in Canada for the treatment of myelofibrosis in adults who have moderate to severe anemia

Ojjaara (momelotinib) is the only approved treatment for newly diagnosed and previously treated myelofibrosis patients i who have moderate to severe anemia and other key manifestations associated with...

8 days ago - Benzinga

GSK Steps Up Parkinson’s Focus With US Biotech Deal

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug development for Parkinson’s disease.

9 days ago - BNN Bloomberg

Canada approves GSK's RSV vaccine for adults aged 50 to 59

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said on Tuesday, making it the country's first authorized RSV shot for that age ...

15 days ago - Reuters

DHA and GSK sign a collaboration agreement to raise awareness on adult immunization

Tackling adult immunization education and awareness during the Healthcare Future Summit

16 days ago - Zawya

GSK Pharma sets record date for Rs 12 special interim dividend on November 7, 2024

GlaxoSmithKline Pharmaceuticals Limited (GSK Pharma) has announced the record date for its special interim dividend, set for November 7, 2024. This follows the company’s earlier declaration on October...

17 days ago - Business Upturn